The latest biotech news

News and Trends 22 Sep 2017

EU gives French Biotech €20M to Continue the Fight Against Antibiotic Resistance

Da Volterra has been boosted by a €20M loan to speed up the development of solutions for the antibiotic resistance crisis. The French biopharma concentrates on the prevention and treatment of serious infections. This is a big area of interest due to rapidly rising antibiotic resistance. The company has been boosted by a €20M loan from the […]

September 22, 2017 - 3 minutesmins - By Alex Dale

helloscience novozymes water scarcity3 1

News and Trends 21 Sep 2017

Novozymes Launches HelloScience to Encourage Global Collaboration on Big Issues

The HelloScience platform will provide an online network where solutions for the world’s biggest challenges can be developed. First up, water scarcity. Novozyme’s new online network, HelloScience, will provide a space for innovators, start-ups, companies, and others to come together and work on developing solutions for some of the world’s biggest challenges. One of the […]

September 21, 2017 - 2 minutesmins - By Alex Dale

News and Trends 21 Sep 2017

European Commission Approves Merck’s PD-L1 Inhibitor for Aggressive Skin Cancer

Merck and Pfizer’s new immunotherapy, avelumab, has been approved by the European Commission to treat metastatic Merkel cell carcinoma, an aggressive form of skin cancer. The approval is based on data from a Phase II study, JAVELIN Merkel 200, where subjects responded well to treatment for a sustained period of time. Earlier this year, Avelumab was […]

September 21, 2017 - 3 minutesmins - By Alex Dale

News and Trends 20 Sep 2017

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

The FDA has backed Kiadis Pharma’s lead blood cancer product by granting it the Regenerative Medicine Advanced Therapy designation. Kiadis Pharma, based in Amsterdam, develops products to make bone marrow transplants for the treatment of blood cancer and inherited blood disorders safer and more effective. Their lead T cell immunotherapy candidate, ATIR101, reduces the risk of complications, and […]

September 20, 2017 - 2 minutesmins - By Alex Dale

biotech portugal vesalius biocapital fund

News and Trends 20 Sep 2017

Biotech in Portugal gets a Boost with New Investment Fund

Vesalius Biocapital and the Portuguese National Promotional Bank have announced a new joint venture that will invest in late-stage healthcare companies. The Instituição Financeira de Desenvolvimento (IFD), or Portuguese National Promotional Bank, is launching its first joint investment with an international VC, Vesalius Biocapital. Though its size hasn’t been revealed yet, the new fund is a 50/50 venture […]

September 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2017

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

A British-American collaboration’s once-daily triple therapy inhaler has been approved for use by appropriate COPD patients in the US. A new triple therapy inhaler for chronic obstructive pulmonary disease (COPD), Trelegy Ellipta, has been developed by British giant GSK in collaboration with Innoviva in the US. The inhaler is targeted at patients who are struggling with airflow […]

September 20, 2017 - 2 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, which help the immune system to target virally and bacterially infected cells, respectively. In particular, […]

September 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […]

September 18, 2017 - 1 minutemin - By Alex Dale

News and Trends 18 Sep 2017

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […]

September 18, 2017 - 2 minutesmins - By Alex Dale

Morphosys Janssen Guselkumab approval psoriasis

News and Trends 18 Sep 2017

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […]

September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Sep 2017

How Does it Feel Like to be a Slime Mold in Berlin?

Bioartist Heather Barnett explores the amusing world of a microorganism that can navigate its way around cities much like a human would do. Physarum polycephalum, commonly known as slime mold, is a fascinating microorganism. This yellow single-celled being has no brain or nervous system, but it can play piano and write Hebrew. It can also […]

September 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Sep 2017

New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain

Levicept’s Phase I study will test their new pain relief candidate’s safety and tolerability in healthy individuals and osteoarthritis patients. Levicept, based in Sandwich, UK, focuses on the development of its pain relief candidate, LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc). The Phase I study is the company’s maiden voyage into the clinic, and it will test the […]

September 15, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

EU gives French Biotech €20M to Continue the Fight Against Antibiotic Resistance

Novozymes Launches HelloScience to Encourage Global Collaboration on Big Issues

European Commission Approves Merck’s PD-L1 Inhibitor for Aggressive Skin Cancer

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

Biotech in Portugal gets a Boost with New Investment Fund

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Update: After 25 years, MorphoSys Gets its First Antibody Approved

How Does it Feel Like to be a Slime Mold in Berlin?

New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!